Clinical Significance of Serum Antithrombin III Activity After Hepatectomy for Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Clinical Significance of Serum Antithrombin III Activity After Hepatectomy for Hepatocellular Carcinoma

Published:2021 Issue:2 Volume:64 Page:168-175
ISSN:1346-8049
Container-title:Yonago Acta Medica
language:en
Short-container-title:Yonago Acta Med.

Author:

Tokuyasu Naruo¹,Amisaki Masataka¹,Hanaki Takehiko¹,Murakami Yuki¹,Morimoto Masaki¹,Uchinaka Ei¹,Yagyu Takuki¹,Goto Keisuke¹,Matsunaga Tomoyuki¹,Yamamoto Manabu¹,Takano Shuichi¹,Sakamoto Teruhisa¹,Honjo Soichiro¹,Hasegawa Toshimichi¹,Fujiwara Yoshiyuki¹

Affiliation:

1. Division of Gastrointestinal and Pediatric Surgery, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan

Publisher

Tottori University Faculty of Medicine

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/yam/64/2/64_2021.05.007/_pdf

Reference33 articles.

1. 1. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-43. PMID:22424438, DOI:10.1016/j.jhep.2011.12.001

2. 2. Japan Society of Hepatology. Clinical practice guidelines for hepatocellular carcinoma (2013 version). Tokyo: Kanehara; 2013. 223 p.

3. 3. Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010;125:490-3. PMID:20097409, DOI:10.1016/j.thromres.2009.12.023

4. 4. Hepner M, Karlaftis V. Antithrombin. Methods Mol Biol. 2013;992:355-64. PMID:23546728, DOI:10.1007/978-1-62703-339-8_28

5. 5. Asakura H. [DIC: state-of-the-art in diagnosis and management]. Rinsho Ketsueki. 2019;60:659-66. Japanese with English abstract. PMID:31281159, DOI:10.11406/rinketsu.60.659